The efficacy of the D2 and 5-HT2 antagonist risperidone (R 64 766) in the treatment of chronic psychosis: An open dose-finding study
- 31 October 1989
- journal article
- clinical trial
- Published by Elsevier BV in Schizophrenia Research
- Vol. 2 (4-5), 411-415
- https://doi.org/10.1016/0920-9964(89)90034-0
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Pharmacological profile of ritanserin: A very specific central serotonin S2-antagonistDrug Development Research, 1988
- The effects of chronic ritanserin treatment on sleep and the neuroendocrine response to l-tryptophanPsychopharmacology, 1987
- Electroencephalographic Sleep in Young, Never-Medicated SchizophrenicsArchives of General Psychiatry, 1987
- Negative and positive schizophrenic syndromes after the acute phase: A prospective follow-upComprehensive Psychiatry, 1986
- 5-Hydroxytryptamine-2 antagonist increases human slow wave sleepBrain Research, 1986
- The Two-syndrome Concept: Origins and Current StatusSchizophrenia Bulletin, 1985
- Protein Synthesis, Bodily Renewal and the Sleep-Wake CycleClinical Science, 1983
- Blood Tryptophan Metabolism in Chronic SchizophrenicsArchives of General Psychiatry, 1981
- Increased Whole Blood Serotonin Concentrations in Chronic Schizophrenic PatientsArchives of General Psychiatry, 1981
- Positive and Negative Schizophrenic Symptoms and the Role of DopamineThe British Journal of Psychiatry, 1980